000076990 001__ 76990
000076990 005__ 20240104111810.0
000076990 0247_ $$2doi$$a10.1371/journal.pone.0210752
000076990 0248_ $$2sideral$$a109675
000076990 037__ $$aART-2019-109675
000076990 041__ $$aeng
000076990 100__ $$0(orcid)0000-0002-2898-4561$$aRando, A.
000076990 245__ $$aChemotherapeutic agent 5-fluorouracil increases survival of SOD1 mouse model of ALS
000076990 260__ $$c2019
000076990 5060_ $$aAccess copy available to the general public$$fUnrestricted
000076990 5203_ $$aAmyotrophic lateral sclerosis (ALS) is a lethal motor neuron disease with no cure. Currently there are only two ALS drugs approved by the FDA, both with a limited therapeutic effect. In the search for drug candidates for ALS, we studied the effect of known stem cell mobilizing agents (treatment) and antimetabolite 5-fluorouracil (5-FU) (anti-treatment) in SOD1G93A model of ALS. Surprisingly, we found that anti-cancer drug 5-FU increases lifespan, delays the disease onset and improves motor performance in ALS mice. Although we were not able to demonstrate the mechanistic basis of the beneficial 5-FU action in ALS mice, our findings suggest that 5-FU or similar drugs are possible drug candidates for the treatment of motor neuron diseases through drug repurposing.
000076990 536__ $$9info:eu-repo/grantAgreement/ES/FIS/PI14-00947$$9info:eu-repo/grantAgreement/ES/FIS/PI17-00949$$9info:eu-repo/grantAgreement/ES/ISCIII/CB06-05-1105$$9info:eu-repo/grantAgreement/ES/ISCIII/RD12-0019-0011$$9info:eu-repo/grantAgreement/ES/ISCIII/RD16-0011-0035
000076990 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000076990 590__ $$a2.74$$b2019
000076990 592__ $$a1.023$$b2019
000076990 591__ $$aMULTIDISCIPLINARY SCIENCES$$b27 / 71 = 0.38$$c2019$$dQ2$$eT2
000076990 593__ $$aMultidisciplinary$$c2019$$dQ1
000076990 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000076990 700__ $$0(orcid)0000-0002-7955-7164$$ade la Torre, M.$$uUniversidad de Zaragoza
000076990 700__ $$aMartinez-Muriana, A.
000076990 700__ $$0(orcid)0000-0001-5740-0185$$aZaragoza, P.$$uUniversidad de Zaragoza
000076990 700__ $$aMusaro, A.
000076990 700__ $$aHernández, S.
000076990 700__ $$aNavarro, X.
000076990 700__ $$0(orcid)0000-0002-7243-1737$$aToivonen, J.M.$$uUniversidad de Zaragoza
000076990 700__ $$0(orcid)0000-0001-5687-6704$$aOsta, R.$$uUniversidad de Zaragoza
000076990 7102_ $$11001$$2420$$aUniversidad de Zaragoza$$bDpto. Anatom.,Embri.Genét.Ani.$$cÁrea Genética
000076990 773__ $$g14, 1 (2019), e0210752 [16pp]$$pPLoS One$$tPLoS ONE$$x1932-6203
000076990 8564_ $$s1970540$$uhttps://zaguan.unizar.es/record/76990/files/texto_completo.pdf$$yVersión publicada
000076990 8564_ $$s101892$$uhttps://zaguan.unizar.es/record/76990/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000076990 909CO $$ooai:zaguan.unizar.es:76990$$particulos$$pdriver
000076990 951__ $$a2024-01-04-11:02:08
000076990 980__ $$aARTICLE